Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P56159

UPID:
GFRA1_HUMAN

ALTERNATIVE NAMES:
RET ligand 1; TGF-beta-related neurotrophic factor receptor 1

ALTERNATIVE UPACC:
P56159; A8KA21; O15507; O43912

BACKGROUND:
The GDNF family receptor alpha-1, known alternatively as RET ligand 1, serves as a critical component in the signaling pathway for GDNF, influencing the activation of the RET receptor. This interaction is essential for the development and maintenance of the renal and urinary systems, highlighting the receptor's significance in embryonic kidney formation.

THERAPEUTIC SIGNIFICANCE:
Linked to the devastating condition Renal hypodysplasia/aplasia 4, GDNF family receptor alpha-1's involvement suggests a potential target for therapeutic intervention. Exploring the receptor's function and its role in disease mechanisms offers a promising avenue for developing treatments for patients suffering from this life-threatening disorder.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.